ELICIO THERAPEUTICS INC (ELTX)

US28657F1030 - Common Stock

10.05  +0.67 (+7.14%)

News Image
4 days ago - BusinessInsider

ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Elicio Therapeutics (NASDAQ:ELTX) just reported results for the first quarter o...

News Image
4 days ago - InvestorPlace

ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024

ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

News Image
4 days ago - Elicio Therapeutics, Inc.

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response...

News Image
25 days ago - Elicio Therapeutics, Inc.

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

News Image
a month ago - Elicio Therapeutics, Inc.

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific...

News Image
2 months ago - InvestorPlace

ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023

ELTX stock results show that Elicio Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Elicio Therapeutics (NASDAQ:ELTX) just reported results for the fourth quarter ...

News Image
2 months ago - Elicio Therapeutics, Inc.

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were...

News Image
2 months ago - Elicio Therapeutics, Inc.

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

News Image
2 months ago - Elicio Therapeutics

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

News Image
3 months ago - Elicio Therapeutics Inc.

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

News Image
4 months ago - Elicio Therapeutics Inc.

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable...

News Image
4 months ago - Elicio Therapeutics Inc.

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor...

News Image
4 months ago - Elicio Therapeutics Inc.

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...

News Image
4 months ago - Elicio Therapeutics Inc.

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of all solid tumors,...

News Image
4 months ago - InvestorPlace

Unity Layoffs 2024: What to Know About the Latest U Job Cuts

Unity layoffs are on the way as the video game software company reveals plans to cut 1,800 jobs to focus on its core business.

News Image
4 months ago - InvestorPlace

Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?

Cyclacel Pharmaceuticals stock is slipping on Tuesday after shares of CYCC rallied on Monday alongside it regaining Nasdaq compliance.

News Image
4 months ago - InvestorPlace

Why Is Grifols (GRFS) Stock Down 38% Today?

Grifols stock is falling hard as investors sell GRFS shares after the company was hit with a short report from Gotham City Research.

News Image
4 months ago - InvestorPlace

Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today?

Elicio Therapeutics stock is up with heavy trading of ELTX shares are posting positive preliminary results from a Phase 1 clinical trial.